Physician profile
Ryan Whitcomb
NPI 1710221684
$2,797.34
in general payments reported to CMS, 2019-2025
22 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $686 · 2022: $224 · 2023: $1,456 · 2024: $135 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Food and Beverage | $588.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,715.99 | 2021-2025 | |
| Emd Serono, INC. | $337.28 | 2021-2025 | Mavenclad |
| Sk Life Science, INC. | $128.16 | 2025 | |
| Amgen INC. | $88.99 | 2021 | |
| Celgene Corporation | $61.58 | 2021 | |
| Ucb, INC. | $57.43 | 2021 | |
| Lilly USA, LLC | $43.04 | 2021 | |
| Adamas Pharmaceuticals, INC. | $40.62 | 2021 | |
| Janssen Pharmaceuticals, INC | $40.27 | 2021 | |
| Lundbeck LLC | $31.74 | 2021 | |
| Sunovion Pharmaceuticals INC. | $30.73 | 2021 | |
| Neurocrine Biosciences, INC. | $26.17 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $24.97 | 2021 | |
| Eisai INC. | $23.37 | 2021 | |
| Acadia Pharmaceuticals INC | $21.01 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $20.75 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.90 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.29 | 2021 | |
| Genzyme Corporation | $18.62 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.17 | 2021 | |
| Argenx US, INC. | $14.72 | 2023 | Vyvgart |
| Amneal Pharmaceuticals LLC | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Whitcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.